Single-cell techniques offer exciting, new ways to understand personalized medicine and research. Developing these techniques at Bio-Rad is Dr. Kelly Kaihara, the third guest on Brilliant Science. Read about what makes single-cell analysis different and Kaihara’s perspective on its potential moving forward.
Immuno-oncology, or cancer immunotherapy, research focuses heavily on the various types of cells and their behavior in cancer, so the use of flow cytometry to interrogate these cells is a no brainer. See how flow cytometry fits in this growing field of research and how it can help identify new targets and improve drug design to generate more effective and safer cancer therapeutics.
Our immune systems could soon hold the key to rewriting disease and disorder treatments. Studying the inner workings of the immune system’s primary weapon, the macrophage, with the help of CRISPR is Dr. Adam Hoppe at SDSU. Read more about his exciting work and what he hopes to accomplish next.
The advent of CRISPR as a gene editing tool appears to have revolutionized drug discovery and development in a very short time. CRISPR-Cas9 technology is also being utilized to target HIV, to mutate or cut out the provirus. Read about what’s new in potential treatments for HIV and the challenges facing the industry.
On the scientific horizon are possibilities of curing genetic disorders and altering disease management — all because of CRISPR. Investigating exciting approaches to reversing the effects of muscular dystrophy with the help of CRISPR is Dr. Chengzu Long at NYU. Read more about his life, his work, and where he sees CRISPR going next.
In this podcast, biosimilar key opinion leader Dr. Paul Rhyne provides an overview of the current state of biosimilars and their global impact. Leveraging his 20+ years of experience in developing biologics, he discusses how cost and patient access play a big role in this new field of research.
It is hoped that the development of biosimilars will lead to more accessible and cost-effective treatment options. Here we explore the current opportunities for biosimilars in rheumatoid arthritis and discuss the opportunities and concerns tied to their use.
Biosimilars are gaining in popularity and estimates predict that the U.S. could save between $40–250 billion in healthcare costs over the next decade by switching from biologics to biosimilars. See how biosimilars have gained in popularity recently, the challenges the U.S. faces in developing them, and what the future holds.
Cancer kills eight million people annually worldwide; this number will increase to 13 million by 2020. Lung, breast, colorectal, and prostate cancer are the four most commonly diagnosed cancers. Meaningful developments in immuno-oncology, or cancer immunotherapy, treatments are important now more than ever. Learn about some of the newer immunotherapies, including BiTE Antibodies and vaccines, and the companies developing them.